Abstract
Background: Lung cancer is one of the most common types of cancer worldwide and is characterized by a poor prognosis, related to both late diagnosis and lack of effective treatments. In the last years, microRNAs (miRNAs) have been demonstrated to have an important role in tumor microenvironment and immune regulation. These RNAs can be categorized into tumor-suppressor genes, such as let-7 family and miR-34, and oncogenes such as miR-221 and miR-222. Curcumin is a bioactive polyphenol that is documented to have promising anticancer activity, and to be well tolerated in humans.
Methods: The present review aims to gather available evidence on the involvement of mRNAs in the therapeutic effects of curcumin against lung cancer.
Results: The anti-cancer properties of curcumin against lung cancer have been shown in both cellular and experimental models and are mediated by modulation of several molecular targets that regulate the expression of transcription factors, inflammatory cytokines, enzymes, growth factors, receptors, adhesion molecules, antiapoptotic proteins, and cell cycle proteins, leading to cell apoptosis, inhibition of cell proliferation and migration, and also chemo- and radio-sensitization of lung cancer cells. Recent studies have documented that pharmacological effects of curcumin in lung cancer are also mediated by modulation of several miRNAs, such as downregulation of oncogenic miR-21 and upregulation of oncosuppressive miR-192-5p and miR-215.
Conclusion: Further studies are necessary to explore this very promising field and the link between regulation of oncogenic and tumor-suppressive miRNAs and putative anti-cancer properties of curcumin.
Keywords: Curcumin, epigenetic, lung cancer, MicroRNA, RNA interference, tumor.
Current Pharmaceutical Design
Title:Curcumin and Lung Cancer: the Role of microRNAs
Volume: 23 Issue: 23
Author(s): Diana Lelli, Claudio Pedone, Muhammed Majeed and Amirhosssein Sahebkar*
Affiliation:
- Biotechnology Research Center, Department of Medical Biochemistry, Mashhad, Iran, P.O. Box: 91779-48564,Iran
Keywords: Curcumin, epigenetic, lung cancer, MicroRNA, RNA interference, tumor.
Abstract: Background: Lung cancer is one of the most common types of cancer worldwide and is characterized by a poor prognosis, related to both late diagnosis and lack of effective treatments. In the last years, microRNAs (miRNAs) have been demonstrated to have an important role in tumor microenvironment and immune regulation. These RNAs can be categorized into tumor-suppressor genes, such as let-7 family and miR-34, and oncogenes such as miR-221 and miR-222. Curcumin is a bioactive polyphenol that is documented to have promising anticancer activity, and to be well tolerated in humans.
Methods: The present review aims to gather available evidence on the involvement of mRNAs in the therapeutic effects of curcumin against lung cancer.
Results: The anti-cancer properties of curcumin against lung cancer have been shown in both cellular and experimental models and are mediated by modulation of several molecular targets that regulate the expression of transcription factors, inflammatory cytokines, enzymes, growth factors, receptors, adhesion molecules, antiapoptotic proteins, and cell cycle proteins, leading to cell apoptosis, inhibition of cell proliferation and migration, and also chemo- and radio-sensitization of lung cancer cells. Recent studies have documented that pharmacological effects of curcumin in lung cancer are also mediated by modulation of several miRNAs, such as downregulation of oncogenic miR-21 and upregulation of oncosuppressive miR-192-5p and miR-215.
Conclusion: Further studies are necessary to explore this very promising field and the link between regulation of oncogenic and tumor-suppressive miRNAs and putative anti-cancer properties of curcumin.
Export Options
About this article
Cite this article as:
Lelli Diana, Pedone Claudio, Majeed Muhammed and Sahebkar Amirhosssein*, Curcumin and Lung Cancer: the Role of microRNAs, Current Pharmaceutical Design 2017; 23 (23) . https://dx.doi.org/10.2174/1381612823666170109144818
DOI https://dx.doi.org/10.2174/1381612823666170109144818 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding the Role of Aldose Reductase in Ocular Inflammation
Current Molecular Medicine Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
Current Cancer Drug Targets Upregulation of Cytoskeleton Protein and Extracellular Matrix Protein Induced by Stromal-Derived Nitric Oxide Promotes Lung Cancer Invasion and Metastasis
Current Molecular Medicine Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets The Interactions of Anticancer Agents with Tea Catechins: Current Evidence from Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA
Current Cancer Therapy Reviews Design, Synthesis and Biological Evaluation of 3-(3,4,5-Trimethoxyphenyl)- 5-(2-(5-arylbenzo[b]thiophen-3-yl)oxazol-5-yl)isoxazole Derivatives as Anticancer Agents
Letters in Organic Chemistry Peeking into the Black Box: How Cytokine Antibody Arrays Shed Light on Molecular Mechanisms of Breast Cancer Development and its Treatment
Current Proteomics Endobronchial Ultrasound-guided Transbronchial Needle Aspiration
Reviews on Recent Clinical Trials Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer
Current Medicinal Chemistry Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Poly(ethylene glycol)-polypeptide Copolymer Micelles for Therapeutic Agent Delivery
Current Pharmaceutical Biotechnology HOXA4-Dependent Transcriptional Activation of AXL Promotes Cisplatin- Resistance in Lung Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
Current Cancer Therapy Reviews Formulation and Characterization of Gefitinib-loaded Polymeric Nanoparticles Using Box-Behnken Design
Current Nanomedicine